Zarrabian Saiid 4
4 · DelMar Pharmaceuticals, Inc. · Filed Nov 7, 2017
Insider Transaction Report
Form 4
Zarrabian Saiid
DirectorInterim CEO
Transactions
- Award
Options (Right to Buy)
2017-11-03+120,000→ 120,000 totalExercise: $0.87Exp: 2027-11-03→ Common Stock (120,000 underlying)
Footnotes (1)
- [F1]The option vests in full on the first anniversary of the date of grant.